Oncology drug discovery applications using the FMAT 8100 HTS system |
| |
Authors: | Lee Jennifer Y Miraglia Sheri Yan Xiongwei Swartzman Elana Cornell-Kennon Susan Mellentin-Michelotti Julia Bruseo Charles France Dennis S |
| |
Affiliation: | Novartis Pharmaceuticals Corporation, NJ 07901, USA. |
| |
Abstract: | High-throughput screening (HTS) for potential anticancer agents requires a broad portfolio of assay platforms that may include kinase enzyme assays, protein-protein binding assays, and functional cell-based apoptosis assays. The authors have explored the use of fluorometric microvolume assay technology (the FMAT 8100 HTS System) in three distinct homogeneous HTS assays: (1). a Src tyrosine kinase enzyme assay, (2). a Grb2-SH2 protein-peptide interaction assay, and (3). an annexin V binding apoptosis assay. Data obtained from all three assays suggest that the FMAT system should facilitate the implementation of homogeneous assays for a wide variety of molecular targeted and cell-based screens. |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |
|